+0.11 (+0.75%)
Dilution Risk
R&D Expenses
25.63 M
Operating CF
-17.30 M
Total Assets
189.74 M
Total Liabilities
38.51 M
Equity
151.23 M
D/E Ratio
12,345
Cash Position
186.63 M
Monthly Burn
5.77 M
Runway
30.4 mo
Burn Trend
SEC Filing
May 13, 2026locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 Readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 3 Readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 3 Readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Nervous System |
Dated clinical, regulatory & corporate events for Immunic, Inc.
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-09-10 | Vidofludimus calcium (IMU-838) | Phase 2/3 data readout | Phase 2/3 | — | – | – | – |
2024-09-10 | Vidofludimus calcium (IMU-838) | Phase 2/3 data readout | Phase 2/3 | — | – | – | – |
2024-09-10 | Vidofludimus calcium (IMU-838) | Phase 2/3 data readout | Phase 2/3 | — | – | – | – |
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMU-838 Small molecule | Multiple Sclerosis | Phase 3 | NCT05134441 | 44% | $3.1B | ACTIVE NOT_RECRUITING | 1,121 | FAST | B (69) | Sep 1, 2033 | MODERATE_RISK | LOW May 26, 2026 |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
vidofludimus calcium | progressive multiple sclerosis | Phase 2 | 2026-05-28 | results consistently favored vidofludimus calcium over placebo Read More | Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis Read More | |
vidofludimus calcium | progressive multiple sclerosis | Phase 2 | 2026-05-28 | results consistently favored vidofludimus calcium over placebo Read More | Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis Read More | |
vidofludimus calcium | progressive multiple sclerosis | Phase 2 | 2026-05-28 | results consistently favored vidofludimus calcium over placebo Read More | Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis Read More |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Immunic, Inc. announced its participation in several investor conferences in July 2026. Key executives will engage in one-on-one meetings and discussions at the Leerink Partners Therapeutics Forum, B. Riley Securities Mind, Muscle & Vision Summit, and LifeSci Capital SF Biotech Forum. The company is also progressing its lead therapy, vidofludimus calcium, in Phase 3 clinical trials for relapsing multiple sclerosis.
Read more →Immunic, Inc. announced its participation in several key conferences in June 2026, including the H.C. Wainwright Neuro Perspectives Summit and the BIO International Convention. The company's management will engage in discussions and presentations about their ongoing development programs, particularly focusing on their lead candidate, vidofludimus calcium, which is in phase 3 trials for multiple sclerosis. This involvement highlights Immunic's commitment to advancing its therapeutic pipeline and fostering investor relations.
Read more →Immunic, Inc. presented new data from its Phase 2 CALLIPER trial for vidofludimus calcium at the CMSC Annual Meeting 2026. The findings highlight a novel statistical approach to assess disability changes in progressive multiple sclerosis, showing favorable safety and tolerability. Patient-reported outcomes indicated no adverse mood effects, reinforcing the drug's potential in treating the condition.
Read more →Immunic, Inc. has appointed Erik Lundgren as its new CEO, effective June 1, 2026. Lundgren, with extensive experience in the biopharmaceutical industry, will lead the company as it advances its lead asset, vidofludimus calcium, through late-stage clinical trials for multiple sclerosis. His prior success with Ocrevus® is expected to be instrumental in Immunic's transition to a commercial-stage company.
Read more →Immunic, Inc. has appointed Michael W. Bonney as Chair of the Board of Directors, effective May 16, 2026. Bonney, a seasoned biopharmaceutical executive, has over 30 years of experience, including significant roles at Biogen and Cubist Pharmaceuticals. His expertise in multiple sclerosis and commercialization will be pivotal as Immunic advances its lead program, vidofludimus calcium, through clinical trials.
Read more →Immunic, Inc. reported its Q1 2026 financial results, highlighting the appointment of Michael A. Panzara as Chief Medical Officer and the ongoing Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis. The company raised $200 million in a private placement, with expectations for top-line data by the end of 2026. Despite a net loss of $32.6 million, the company is positioned for potential commercialization and further development in multiple sclerosis treatments.
Read more →Immunic, Inc. announced its participation in several investor and medical conferences in May 2026, including the Bio€quity Europe and the Consortium of Multiple Sclerosis Centers Annual Meeting. The company will present late-breaking and additional poster presentations showcasing their research on vidofludimus calcium, a treatment for multiple sclerosis. This engagement emphasizes Immunic's commitment to advancing therapies for neurologic diseases.
Read more →Immunic, Inc. has appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer. Dr. Panzara, with over 25 years of experience in neurology, will lead the company's development organization and is expected to play a key role in advancing the clinical development of vidofludimus calcium. His appointment comes as Immunic prepares for pivotal trials in multiple sclerosis.
Read more →Immunic, Inc. announced a 1-for-10 reverse stock split effective April 27, 2026, to meet contractual obligations. The decision was approved by stockholders on April 14, 2026. This action will reduce the number of outstanding shares from approximately 136 million to 13.6 million while maintaining the same ownership percentages for stockholders.
Read more →Immunic, Inc. announced its participation in key scientific and medical conferences in April 2026, including the Neuroimmunology Drug Development Summit and the American Academy of Neurology Annual Meeting. At these events, the Chief Scientific Officer will present findings on their lead asset, vidofludimus calcium, which is in phase 3 trials for multiple sclerosis. The company aims to highlight its unique therapeutic approach combining neuroprotective and anti-inflammatory properties.
Read more →Immunic, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement. The company achieved this as its stock price remained above $1.00 for at least 20 consecutive business days. This compliance is crucial for its continued listing on the Nasdaq Capital Market. Immunic is focused on developing therapies for neurologic diseases, with its lead program currently in phase 3 trials.
Read more →Immunic, Inc. has appointed Jon Congleton to its Board of Directors, effective March 27, 2026. Congleton, a veteran in the biopharmaceutical industry with extensive experience in CNS and drug commercialization, is expected to play a crucial role in advancing Immunic's lead program, vidofludimus calcium, through pivotal clinical milestones. His background includes significant contributions to the launch of Copaxone for multiple sclerosis.
Read more →Immunic, Inc. has received a significant European patent for its lead asset, vidofludimus calcium, which covers label-relevant dosing regimens and protects all forms of the drug. This patent ensures exclusive rights in Europe until at least 2038, with potential extensions to 2043, enhancing Immunic's intellectual property strategy. The company already has multiple layers of patent protection in the U.S. and globally, strengthening its position as it progresses through late-stage clinical trials. Vidofludimus calcium has demonstrated encouraging efficacy in treating multiple sclerosis in prior studies.
Read more →Immunic, Inc. announced its participation in several investor conferences in March 2026. The company is focused on developing novel oral therapies for neurologic and gastrointestinal diseases, with its lead program, vidofludimus calcium, currently in phase 3 clinical trials for relapsing multiple sclerosis. Top-line data from these trials is expected by the end of 2026.
Read more →Immunic, Inc. reported its financial results for 2025 and provided a corporate update, highlighting the progress of its Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis. The company raised $200 million in a private placement, with plans for a total of $400 million, which will support ongoing trials and preparations for a potential NDA submission in 2027. The drug aims to address both neuroprotective effects and inflammation in MS treatment.
Read more →Immunic, Inc. has successfully closed an oversubscribed private placement financing, securing $200 million in upfront proceeds. This funding will support the completion of Phase 3 ENSURE trials for relapsing multiple sclerosis and the initiation of a Phase 3 trial for primary progressive multiple sclerosis. The company also anticipates an additional $200 million in potential proceeds through warrants. Overall, this financing positions Immunic to advance its clinical programs and transition into a commercial organization.
Read more →Immunic, Inc. has announced an oversubscribed private placement of up to $400 million to fund its transition into a commercial-stage company. The funds will support the completion of Phase 3 trials for its lead candidate, vidofludimus calcium, in relapsing and progressive multiple sclerosis. Additionally, the company is undergoing leadership changes to align with its commercial strategy, including the appointment of Simona Skerjanec as interim Chairperson.
Read more →Immunic, Inc. presented additional data from its Phase 2 CALLIPER trial for vidofludimus calcium at the ACTRIMS Forum 2026. The findings indicate that the treatment significantly reduces MRI markers of both acute and chronic inflammation in patients with progressive multiple sclerosis. Additionally, the drug shows promise in lowering Epstein-Barr virus reactivations, which may contribute to disease progression.
Read more →Immunic, Inc. has completed enrollment for its Phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis, with top-line data expected by the end of 2026. The drug has shown promising results in previous trials, demonstrating neuroprotective effects and favorable safety profiles. Additionally, Immunic is advancing its pipeline with IMU-856, targeting gastrointestinal disorders.
Read more →Immunic, Inc. announced that CEO Daniel Vitt will participate in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference on December 4, 2025. The conference will take place from December 2-4 in Coral Gables, FL. Immunic is focused on developing novel therapies for neurological and gastrointestinal diseases, with its lead program in phase 3 trials for multiple sclerosis.
Read more →Immunic, Inc. reported promising data from its clinical trials for vidofludimus calcium, particularly in progressive multiple sclerosis. The Phase 2 CALLIPER trial demonstrated significant disability improvement, supporting further development into Phase 3 trials. Additionally, the company highlighted its strong intellectual property position with a new patent allowance. Financial results showed continued losses, but the outlook remains optimistic with upcoming data expected.
Read more →Immunic, Inc. announced its participation in several industry and investor conferences in November. The company is developing therapies for chronic inflammatory and autoimmune diseases, with its lead program, vidofludimus calcium, currently in phase 3 trials for relapsing multiple sclerosis. Top-line data for this program is anticipated by the end of 2026.
Read more →Immunic, Inc. (Nasdaq: IMUX) has announced its participation in several important scientific and investor conferences throughout October 2025. The conferences include UEGW 2025 in Berlin, where data on its drug candidate IMU-856 will be presented, and the International Society of Neuroimmunology Congress in Japan, showcasing the drug IMU-838. Additionally, the CEO of Immunic will engage in panel discussions at the Roth's Healthcare Opportunities Conference and conduct a fireside chat at H.C. Wainwright. These activities highlight the company's ongoing development of innovative therapies for autoimmune diseases.
Read more →Immunic, Inc. presented promising data on vidofludimus calcium at the ECTRIMS Congress, highlighting its efficacy in improving disability in patients with progressive multiple sclerosis. The Phase 2 CALLIPER trial showed significant results, with a two-fold probability of improvement over placebo. Long-term data from the EMPhASIS trial also indicated favorable safety and tolerability profiles, supporting further investigation in Phase 3 trials.
Read more →Immunic, Inc. has received a Notice of Allowance for a U.S. patent covering dose strengths of vidofludimus calcium for treating progressive multiple sclerosis. This patent is expected to provide protection until 2041, enhancing the company's intellectual property strategy. The announcement follows positive results from the phase 2 CALLIPER trial, which demonstrated the drug's potential to slow disease progression.
Read more →Immunic, Inc. has received a Notice of Allowance from the USPTO for a patent covering dose strengths of vidofludimus calcium for treating progressive multiple sclerosis. This patent, expected to provide protection until 2041, strengthens Immunic's intellectual property portfolio. The announcement follows positive results from the phase 2 CALLIPER trial, indicating the drug's potential to slow disease progression.
Read more →Immunic, Inc. is participating in several investor and scientific conferences throughout September 2025, including the H.C. Wainwright Global Investment Conference and the 41st ECTRIMS Congress in Barcelona. Key management will present an overview of the company and data on their lead drug candidate, vidofludimus calcium, which targets chronic inflammatory and autoimmune diseases. Presentations will include both oral and poster formats detailing significant findings from ongoing clinical trials, reinforcing the company’s commitment to advancing its therapeutic pipeline. This engagement is expected to bolster investor interest and scientific validation of their products.
Read more →Immunic, Inc. reported positive results for its lead asset, vidofludimus calcium, in treating multiple sclerosis. The Phase 2 CALLIPER trial demonstrated significant reductions in disability worsening, while enrollment for the Phase 3 ENSURE trials has been completed. The company raised $70.1 million to support its clinical programs, although it reported a net loss of $27 million for Q2 2025 and faces liquidity challenges.
Read more →Immunic, Inc. (Nasdaq: IMUX) reported positive results for its lead therapy, vidofludimus calcium, in the second quarter of 2025. Notably, the Phase 2 CALLIPER trial demonstrated a significant reduction in disability worsening among progressive multiple sclerosis patients. The company has completed enrollment for its Phase 3 ENSURE trials, with anticipated top-line data expected by the end of 2026. Additionally, a strong financial position has been bolstered by recent fundraisings, enabling further development of its therapies.
Read more →Immunic, Inc. reported encouraging long-term data from its Phase 2 EMPhASIS trial of vidofludimus calcium for relapsing-remitting multiple sclerosis. At Week 144, 92.3% of patients were free of 12-week confirmed disability worsening. The treatment demonstrated a favorable safety profile, with no new safety signals emerging over 5.5 years. This data supports the potential of vidofludimus calcium to effectively manage MS and improve patient outcomes.
Read more →Immunic, Inc. has completed enrollment for its Phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis (RMS), with top-line data expected by the end of 2026. Additionally, new data from the Phase 2 CALLIPER trial in progressive multiple sclerosis (PMS) further supports the drug's neuroprotective potential. The trials involve over 2,200 patients across multiple countries, aiming to evaluate the drug's efficacy and safety.
Read more →Immunic, Inc. has successfully concluded an oversubscribed underwritten public offering, raising approximately $65 million to support its clinical pipeline. The offering includes pre-funded and series warrants, with the potential for total proceeds to reach $130 million. The company plans to utilize the funds for ongoing clinical trials, particularly for its lead therapy aimed at chronic inflammatory conditions. This offering highlights Immunic's ongoing efforts to advance its innovative therapeutic candidates and underscores investor confidence in the company’s future prospects.
Read more →Immunic, Inc. announced its participation in several investor and scientific conferences during June 2025. The CEO will present an overview at the Jefferies Healthcare Conference, and preclinical data will be highlighted at the RSC Anglo-Nordic Medicinal Chemistry Symposium. Additionally, Immunic will engage in various networking opportunities at the BIO International Convention and the European Academy of Neurology Congress while presenting findings related to their lead asset, vidofludimus calcium, in multiple sessions throughout these events.
Read more →Immunic, Inc. has announced the completion of a $65 million underwritten public offering, which was oversubscribed. This fundraising effort involves the sale of warrants to purchase common stock, and the company expects to close the transaction by June 3, 2025. The funds raised will be utilized to finance clinical trials and other general corporate purposes. The company’s lead therapy, vidofludimus calcium (IMU-838), is currently in phase 3 trials, aiming to address chronic inflammatory conditions, with potential to receive additional funds if corresponding warrants are exercised.
Read more →Immunic, Inc. has announced a proposed underwritten public offering of pre-funded warrants and Series A and B warrants to purchase shares of its common stock. The offering is intended to raise funds for the company's clinical trials and general corporate purposes. The securities will be offered under a previously filed shelf registration statement with the SEC. Immunic's lead therapy, vidofludimus calcium, is in phase 3 clinical trials for relapsing multiple sclerosis, with promising preliminary results from earlier studies.
Read more →Immunic, Inc. announced its upcoming participation in several key scientific and industry conferences throughout May 2025. They will present findings from clinical trials on their therapies IMU-856 and vidofludimus calcium, targeting conditions such as celiac disease and multiple sclerosis. These presentations underscore Immunic's commitment to advancing research in chronic inflammatory and autoimmune diseases. However, the company also acknowledges substantial risks associated with forward-looking statements and the unpredictable nature of clinical trials.
Read more →Immunic, Inc. announced positive results from its Phase 2 CALLIPER trial of vidofludimus calcium in patients with primary progressive multiple sclerosis (PPMS). The trial demonstrated a 30% reduction in the risk of confirmed disability worsening events compared to placebo, along with a favorable safety profile. The results suggest that vidofludimus calcium may provide a novel treatment option for patients with progressive forms of MS, addressing significant unmet medical needs.
Read more →Immunic announced positive results from its Phase 2 CALLIPER trial of vidofludimus calcium for treating primary progressive multiple sclerosis (PPMS). The trial indicated a 30% reduction in the risk of disability worsening compared to placebo, with consistent efficacy observed across different patient subsets. Safety and tolerability were confirmed to be favorable, with no new safety concerns arising. The promising outcomes suggest that vidofludimus calcium may represent a novel treatment option for patients suffering from progressive forms of MS, where there is a significant unmet medical need.
Read more →Immunic, Inc. has announced the completion of a registered direct offering, raising approximately $5.1 million through the sale of 5,666,667 shares at $0.90 each. The proceeds will be utilized to support clinical trials and general corporate purposes. This offering follows a previously filed shelf registration statement with the SEC, and was led by Aberdeen Investments. Immunic continues to develop its portfolio of therapies for autoimmune diseases, with its lead candidate currently in clinical trials.
Read more →Immunic, Inc. has announced a registered direct offering of 5,666,667 shares of common stock at a price of $0.90 per share, expected to raise approximately $5.1 million. The offering, led by Aberdeen Investments, is intended to fund Immunic's clinical trials and general corporate purposes. The transaction is set to close on or about April 10, 2025, pending customary closing conditions. Immunic's pipeline includes therapies for chronic inflammatory and autoimmune diseases, with ongoing clinical trials for its lead candidate, vidofludimus calcium.
Read more →Immunic, Inc. announced its participation in two significant conferences in April 2025: the American Academy of Neurology Annual Meeting and German Biotech Days. At these events, the company will highlight its clinical pipeline, particularly its lead asset, vidofludimus calcium, which is in late-stage clinical trials for multiple sclerosis. The conferences offer an opportunity for Immunic to showcase its advancements and network within the biotechnology community.
Read more →Immunic, Inc. will take part in upcoming scientific and investor conferences in March 2025. The company is set to present two abstracts related to antiviral therapies at the 34th Annual Meeting of the Society for Virology in Hamburg, Germany. Additionally, CEO Daniel Vitt will engage in a fireside chat during the Leerink Partners Global Healthcare Conference in Miami. Immunic is actively developing its clinical pipeline for chronic inflammatory and autoimmune diseases, with its lead candidate currently in late-stage clinical trials.
Read more →Immunic, Inc. presented new data on vidofludimus calcium at the ACTRIMS Forum 2025. These findings suggest that the drug activates the Nurr1 factor, leading to a reduction in neuronal loss and microglial activation in preclinical models. The company anticipates that top-line results from the Phase 2 CALLIPER Trial of vidofludimus calcium will be available in April 2025, which may further clarify the drug's therapeutic potential in progressive multiple sclerosis. The research emphasizes the candidate's promise and its anticipated impact on multiple sclerosis treatment options.
Read more →Immunic, Inc. announced promising results for its oral drug IMU-856, which demonstrated a dose-dependent increase in GLP-1 levels in celiac disease patients during a Phase 1b trial. Additionally, preclinical studies indicated a reduction in body weight gain and food consumption. These findings suggest potential for IMU-856 as a treatment for weight management, with further clinical testing planned.
Read more →Immunic, Inc. announced encouraging findings regarding IMU-856, an oral treatment being developed for celiac disease. Data from a phase 1b clinical trial showed a dose-dependent increase in glucagon-like peptide-1 (GLP-1) levels. Additionally, preclinical studies indicated IMU-856 could reduce body weight gain and food consumption. The company is planning to advance the program to phase 2 clinical trials, suggesting potential applications for weight management.
Read more →Immunic, Inc. will participate in several investor and scientific conferences throughout February 2025, including the BIO CEO & Investor Conference and the 19th Congress of ECCO. At these events, executives will highlight Immunic's pipeline, including presentations on IMU-856, an oral modulator for gut health, and vidofludimus calcium (IMU-838), aimed at treating multiple sclerosis. The participation serves to strengthen the company's visibility and provide updates on clinical progress and research findings.
Read more →Immunic, Inc. (Nasdaq: IMUX) has highlighted its 2024 accomplishments and future milestones, focusing on its lead candidate, vidofludimus calcium. The company anticipates top-line data from the Phase 2 CALLIPER trial in April 2025, alongside positive interim results from its Phase 3 ENSURE trials. Recently strengthened management and a successful $240 million funding placement have positioned the company for sustained development through 2025. However, the full completion of these trials is projected for 2026, highlighting a longer timeline before potential market introduction.
Read more →Immunic, Inc. (Nasdaq: IMUX) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference, scheduled for December 3-5, 2024. CEO Daniel Vitt, along with other executives, will engage in a fireside chat and one-on-one investor meetings at the event. The company is focused on developing orally administered therapies for chronic inflammatory and autoimmune diseases, with its lead program in advanced clinical trials. A webcast of the conference will be available for investors on Immunic's website.
Read more →Immunic, Inc. announced the publication of data from its Phase 1/1b clinical trial of IMU-856 in the peer-reviewed journal, The Lancet Gastroenterology & Hepatology. The trial involved healthy subjects and those with celiac disease, revealing positive effects on gut health and safety. IMU-856 displayed the potential to significantly improve the intestinal barrier, symptoms, biomarkers, and nutrient absorption in celiac disease patients. The results prompt further investigation as Immunic prepares for Phase 2 clinical testing.
Read more →Immunic, Inc. reported positive interim results from its Phase 3 ENSURE program for relapsing multiple sclerosis, confirming that predetermined futility criteria have not been met. The company continues its twin Phase 3 ENSURE trials and anticipates top-line data from the Phase 2 CALLIPER trial in April 2025. Financial results indicate a net loss of $24.4 million for Q3 2024, with ongoing investments in clinical trials.
Read more →Immunic, Inc. reported its financial results for the third quarter of 2024 and provided an update on its clinical trials, highlighting a positive interim analysis of the Phase 3 ENSURE program. The Data Monitoring Committee has recommended that the trials proceed as planned, indicating that predetermined futility criteria were not met. The company's lead asset, vidofludimus calcium, is under investigation for treating multiple sclerosis, with forthcoming data from the Phase 2 CALLIPER trial expected in April 2025. While the company faces a net loss this quarter, the progress of its clinical programs and recent presentations at industry conferences position it favorably.
Read more →Immunic, Inc. has announced it will release its financial results for the third quarter and provide a corporate update on November 7, 2024. The company is advancing its lead product, vidofludimus calcium, which is undergoing phase 3 trials for multiple sclerosis. In addition to financial disclosures, Immunic's webcast will offer insights into their clinical pipeline for inflammatory and autoimmune diseases. They caution that various risks may impact future operations and projections.
Read more →Immunic, Inc. announced its participation in several upcoming industry, scientific, and investor conferences throughout November. Key events include the BIO-Europe in Stockholm and a symposium on immuno-mediated diseases in Florence, where they will present data on their phase 1b clinical trial for IMU-856. Additionally, Immunic will host one-on-one meetings during the Jefferies London Healthcare Conference and conduct a virtual investor summit. The company focuses on developing therapies for chronic inflammatory and autoimmune diseases with notable advancements in their clinical pipeline.
Read more →Immunic, Inc. announced a positive outcome from the interim futility analysis of its Phase 3 ENSURE program for vidofludimus calcium in relapsing multiple sclerosis. The Independent Data Monitoring Committee confirmed that predetermined futility criteria were not met and recommended continuing the trials without changes. The ENSURE program is expected to be completed by 2026, with further milestones anticipated in the coming months.
Read more →Immunic, Inc. has announced a positive outcome from the interim analysis of its phase 3 ENSURE program for vidofludimus calcium in treating relapsing multiple sclerosis. An Independent Data Monitoring Committee (IDMC) determined that predetermined futility criteria were not met, allowing the trial to continue without changes. Completion of the ENSURE trials is anticipated by 2026, supporting confidence in the drug's potential in the oral MS market. The company's next milestone includes the top-line readout from the phase 2 CALLIPER trial in progressive multiple sclerosis expected in April 2025.
Read more →Immunic has presented encouraging data on vidofludimus calcium at the ECTRIMS Congress, showcasing its potential in treating multiple sclerosis. The interim analysis from the CALLIPER trial indicated a significant reduction in neurofilament levels, suggesting effectiveness across various progressive MS subtypes. Additional data highlighted its capability to alleviate post-COVID fatigue potentially linked to Epstein-Barr virus reactivation. Upcoming data readouts and ongoing trials may further substantiate the drug's therapeutic profile.
Read more →Immunic, Inc. has announced the enrollment of the first patient in a phase 2 clinical trial of vidofludimus calcium, targeting Post COVID Syndrome. The trial, sponsored by Goethe University Frankfurt, aims to gather data on the candidate's efficacy in reducing symptoms such as fatigue linked to Epstein-Barr virus reactivation. It will involve 376 patients across 11 clinical sites in Germany. This trial also positions vidofludimus calcium as a potential player in addressing symptoms common in multiple sclerosis patients.
Read more →Immunic, Inc. will host a Multiple Sclerosis R&D Day on September 10, 2024, featuring discussions on their lead asset, vidofludimus calcium. The company will also participate in several scientific and investor conferences throughout September, including the 40th ECTRIMS Congress in Copenhagen, where they will present data on vidofludimus calcium. These events highlight Immunic's commitment to advancing research in chronic inflammatory and autoimmune diseases.
Read more →Immunic, Inc. is set to host a Multiple Sclerosis R&D Day and participate in several scientific and investor conferences throughout September. The events will feature discussions on their lead asset, vidofludimus calcium, among prominent industry experts. The company plans to present new data on multiple sclerosis and celiac disease treatment at various significant conferences. Immunic's ongoing clinical trials and participation in these venues highlight its focus on innovative therapies for chronic inflammatory and autoimmune diseases.
Read more →Immunic, Inc. reported its financial results for Q2 2024, highlighting the appointment of Jason Tardio as COO and Simona Skerjanec to the Board. The company is progressing with its Phase 3 ENSURE trials for relapsing multiple sclerosis and Phase 2 CALLIPER trial for progressive multiple sclerosis. Positive interim results from the CALLIPER trial suggest potential efficacy for vidofludimus calcium. However, the company reported a net loss of approximately $21.4 million for the quarter.
Read more →Immunic, Inc. reported its second-quarter 2024 financial results, highlighting the appointment of Jason Tardio as COO and President. The company is making strides in its clinical development, with ongoing phase 3 and phase 2 trials for its lead asset, vidofludimus calcium, targeting multiple sclerosis. The phase 1b trial of IMU-856 demonstrated positive results in celiac disease patients. However, despite these advancements, the company reported a net loss of approximately $51 million for the first half of the year.
Read more →Immunic, Inc. has announced it will unveil its financial results for the second quarter ended June 30, 2024, along with providing a corporate update on August 8, 2024. The biotech company is developing therapies for chronic inflammatory and autoimmune diseases, with its lead program, vidofludimus calcium, currently undergoing clinical trials. The press release outlines the scheduled webcast for discussing these updates and mentions potential risks associated with forward-looking statements, underlining uncertainties in the biotech landscape.
Read more →Immunic, Inc. has appointed Simona Skerjanec to its board of directors, effective July 22, 2024. Skerjanec brings nearly three decades of pharmaceutical experience, notably leading the successful launch of Roche's Ocrevus for multiple sclerosis. Her expertise is expected to strengthen Immunic's strategic direction as it prepares for late-stage clinical trials of vidofludimus calcium.
Read more →Immunic, Inc. announced the appointment of Simona Skerjanec to its board of directors as of July 22, 2024. Skerjanec brings nearly three decades of experience in the pharmaceutical industry, particularly in neuroscience and rare diseases. Her previous role at Roche included successful commercialization of Ocrevus, a drug for multiple sclerosis. Immunic aims to enhance its strategic direction as it approaches significant clinical milestones for its lead drug, vidofludimus calcium, targeting multiple sclerosis.
Read more →Immunic, Inc. has appointed Jason Tardio as Chief Operating Officer and President, effective July 12, 2024. Tardio, a former executive at Novartis and Biogen, will lead efforts for the potential launch of vidofludimus calcium, a drug in phase 3 trials for multiple sclerosis. Werner Gladdines has been promoted to Chief Development Officer, reflecting the company's growth and commitment to advancing its clinical pipeline.
Read more →Immunic, Inc. announced the appointment of Jason Tardio as Chief Operating Officer and President, effective July 12, 2024. Tardio, a former executive at Novartis and Biogen, will lead efforts to prepare for the launch of vidofludimus calcium, a drug aimed at treating multiple sclerosis. Additionally, current Vice President Werner Gladdines has been promoted to Chief Development Officer. Tardio's extensive experience is expected to bolster Immunic's commercial strategy as it approaches key clinical milestones in its drug development programs.
Read more →Immunic, Inc. (Nasdaq: IMUX) has announced its participation in several industry and scientific conferences in June 2024, including the BIO International Convention and the Pharmaceutical Contract Management Group Assembly. The company will showcase its clinical pipeline focused on orally administered therapies for chronic inflammatory and autoimmune diseases. Key presentations will be made by management members, emphasizing the company's commitment to advancing its drug development initiatives, particularly for multiple sclerosis and gastrointestinal disorders.
Read more →Immunic, Inc. reported its Q1 2024 financial results, highlighting a successful $240 million private placement that extends its cash runway into Q3 2025. The company is advancing its clinical trials for vidofludimus calcium in multiple sclerosis, with promising interim results from the CALLIPER trial. Additionally, Immunic received a new patent for vidofludimus calcium, enhancing its intellectual property portfolio.
Read more →Immunic, Inc. has reported its financial results for Q1 2024, highlighting a strengthened balance sheet following a three-tranche private placement totaling up to $240 million. The company continues to progress in its clinical trials, notably for vidofludimus calcium, targeting relapsing and progressive forms of multiple sclerosis. Immunic has also received a fourth patent for this treatment, extending its defense until 2041. The interim data from ongoing phase trials convey promising results that may elevate treatment standards in multiple sclerosis care.
Read more →Immunic, Inc. is set to participate in several investor and scientific conferences in May 2024, highlighting its ongoing clinical research. Key events include presentations on its drugs IMU-856 and vidofludimus calcium (IMU-838), addressing conditions like celiac disease and multiple sclerosis. These conferences provide a platform for Immunic to share interim data from clinical trials, as well as engage with investors about its therapeutic pipeline and future plans.
Read more →Immunic, Inc. has announced that it will release its financial results for the first quarter ended March 31, 2024, on May 8, 2024, prior to the U.S. markets opening. A webcast will follow at 8:00 am ET, aimed at providing a corporate update and engaging with stakeholders. The company specializes in developing small molecule therapies for chronic inflammatory and autoimmune diseases, with notable progress in clinical trials for its drug vidofludimus calcium.
Read more →Immunic, Inc. announced the publication of extended data from its Phase 2 EMPhASIS trial of vidofludimus calcium in patients with relapsing-remitting multiple sclerosis. The results, published in the journal Neurology® Neuroimmunology & Neuroinflammation, indicate that vidofludimus calcium effectively suppressed gadolinium-enhancing lesions by 78% and 74% for 30 mg and 45 mg doses respectively. The drug's safety profile is consistent with placebo, and it is currently undergoing further trials in two Phase 3 studies and a Phase 2 trial for related conditions. The promising findings highlight the potential of vidofludimus calcium as a treatment option for multiple sclerosis.
Read more →Immunic, Inc. will host a Multiple Sclerosis R&D Day on April 9, 2024, featuring key opinion leaders discussing advancements in MS treatment. The company will also participate in investor conferences, showcasing its late-stage asset, vidofludimus calcium. This engagement highlights Immunic's commitment to addressing chronic inflammatory diseases.
Read more →Immunic, Inc. has announced plans to host a Multiple Sclerosis Research and Development Day on April 9, 2024, where key executives will present the latest developments and clinical data regarding their Nurr1 activator, vidofludimus calcium. The company will also participate in various investor conferences throughout April, enhancing its presence and potential investor engagement. The lead clinical asset is currently in late-stage trials for MS and shows neuroprotective and anti-inflammatory properties. Immunic's pipeline includes additional therapies targeting gastrointestinal diseases.
Read more →Immunic, Inc. announced the receipt of a Notice of Allowance for a patent covering a specific polymorph of vidofludimus calcium, providing crucial intellectual property protection. This patent, intended for the treatment of multiple sclerosis, is part of a multilayered strategy that extends protections into 2041 in the U.S. The company highlights the importance of this patent for its lead asset, vidofludimus calcium, which is currently in late-stage clinical trials. This achievement is expected to enhance the commercial viability of the drug as it continues development in various international markets.
Read more →Immunic, Inc. is set to participate in several investor and scientific conferences throughout March 2024, including the Leerink Partners Global Biopharma Conference and the Frontiers in Medicinal Chemistry Conference. At these events, the company will present abstracts on their research into innovative therapies for chronic inflammatory and autoimmune diseases. Specifically, their lead candidate, vidofludimus calcium, is currently being evaluated in clinical trials for multiple sclerosis. This engagement underscores Immunic's commitment to advancing its clinical pipeline and enhancing visibility among investors and the scientific community.
Read more →Immunic, Inc. presented novel data from its phase 2 CALLIPER and CALVID-1 clinical trials for vidofludimus calcium at the ACTRIMS Forum 2024. The interim analysis showed significant reductions in serum neurofilament light chain levels among progressive multiple sclerosis patients treated with the drug compared to placebo. Additionally, findings suggest the drug may help reduce fatigue in MS patients due to its potential role in preventing Epstein-Barr virus reactivation. The company anticipates releasing additional top-line data from the CALLIPER trial in April 2024.
Read more →Immunic, Inc. reported its year-end financial results for 2023, highlighting a successful $240 million private placement that extends its cash runway into Q3 2025. The company showcased promising interim data from its phase 2 CALLIPER trial for vidofludimus calcium, indicating neuroprotective effects in progressive multiple sclerosis. Additionally, Immunic expanded its patent portfolio, ensuring exclusivity until 2041. The company is also preparing for phase 2 trials of its celiac disease treatment, IMU-856.
Read more →Immunic, Inc. announced positive year-end financial results for 2023, highlighting a successful private placement of up to $240 million that extends its cash runway into the third quarter of 2025. The company shared encouraging interim results from the Phase 2 CALLIPER trial for vidofludimus calcium, showing potential neuroprotective effects in patients with progressive multiple sclerosis. Additionally, the news of an expanded patent portfolio is expected to strengthen market exclusivity for its lead drug. Immunic is also preparing for Phase 2 testing for its second key clinical asset, IMU-856, which has shown promise in treating celiac disease.
Read more →Immunic, Inc. announced that it will release its financial results for the fourth quarter and full year ending December 31, 2023, on February 22, 2024. The announcement includes an invitation to a webcast that will provide both financial data and a corporate update. Immunic's lead therapy, vidofludimus calcium, is in advanced clinical trials for multiple sclerosis, indicating ongoing development focus in chronic inflammatory and autoimmune diseases.
Read more →Immunic, Inc. has reported significant advancements and upcoming milestones for its clinical pipeline, including positive interim analysis from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis. The company also highlighted the promising results from its Phase 1b trial of IMU-856 for celiac disease, suggesting improvements in gut health and disease symptoms. Financially, Immunic announced a private placement of up to $240 million, extending their cash runway into the third quarter of 2025. Additionally, the patent portfolio for vidofludimus calcium has been strengthened, providing protection until 2041 in the United States.
Read more →Immunic, Inc. has announced a private placement funding of up to $240 million through a three-tranche securities purchase agreement. The initial tranche will provide $80 million, set to close soon, with subsequent tranches contingent on certain clinical milestones. The funds aim to support the development of its lead product candidates in treating chronic inflammatory and autoimmune diseases with promising clinical prospects. Notable investors such as BVF Partners L.P. are participating in this offering.
Read more →Immunic, Inc. has received a Notice of Allowance for a new patent covering dosing regimens for vidofludimus calcium in the treatment of multiple sclerosis. This patent is expected to provide protection until 2038, with potential extensions to 2041. The patent adds to the company's existing intellectual property portfolio, which includes patents for specific dose strengths and composition-of-matter. Immunic aims to expand its patent protection further as it progresses towards potential regulatory approval.
Read more →Immunic, Inc. has obtained a Notice of Allowance from the USPTO for a patent covering dosing regimens of vidofludimus calcium for multiple sclerosis (MS). This patent is expected to provide intellectual property protection until 2038, with potential extensions leading to up to 14 years of market exclusivity in the U.S. The company has been actively securing patents for vidofludimus calcium, which is currently being evaluated in clinical trials for MS and other chronic inflammatory diseases.
Read more →Immunic, Inc. reported positive interim results from its Phase 2 CALLIPER trial for vidofludimus calcium, showing improvements in serum neurofilament light chain in patients with progressive multiple sclerosis. The company also announced a Notice of Allowance for a patent related to the treatment of relapsing multiple sclerosis. Despite a net loss of $22.8 million in Q3 2023, Immunic maintains a strong cash position to support ongoing clinical trials.
Read more →Immunic, Inc. reported encouraging third-quarter results, highlighted by a positive interim analysis from the Phase 2 CALLIPER trial, indicating improvements in patients' serum neurofilament light chain levels. The analysis showcased the potential of vidofludimus calcium as a neuroprotective treatment for progressive multiple sclerosis. Additionally, the company is well-funded until September 2024 and has secured a notice of allowance for a U.S. patent related to treating relapsing multiple sclerosis. However, the firm continues to face significant net losses and increased R&D expenses.
Read more →Immunic, Inc. (Nasdaq: IMUX) has announced that it will release its financial results for the third quarter of 2023 on November 14, followed by a corporate update webcast. The company is actively advancing its clinical pipeline, particularly its lead program vidofludimus calcium, which is in Phase 3 trials for multiple sclerosis. Additionally, the next generation compound IMU-856 is on track for a Phase 2 clinical trial, targeting gastrointestinal diseases.
Read more →Immunic, Inc. has received a Notice of Allowance from the USPTO for a patent covering the use of vidofludimus calcium for treating relapsing multiple sclerosis. This patent, which protects dosage strengths ranging from 10 mg to 45 mg, is crucial for the company's ongoing phase 3 trials. The patent's protection is set to last until 2041, bolstering Immunic's intellectual property position around its lead drug. Furthermore, the company has various additional patent applications in progress to enhance exclusivity.
Read more →Immunic, Inc. is set to participate in two major scientific and industry conferences in November. At the Association of European Coeliac Societies conference in Athens, they will present data from their phase 1b trial of IMU-856 for celiac disease. Additionally, their team will attend BIO-Europe in Munich to engage in partnership opportunities. The company continues to advance its clinical pipeline for chronic inflammatory and autoimmune diseases, with IMU-856 and vidofludimus calcium as key focus areas.
Read more →Immunic, Inc. announced positive results from the phase 2 CALDOSE-1 trial of vidofludimus calcium for ulcerative colitis at UEGW 2023. The trial data indicated significant clinical remission rates during the maintenance phase, contrasting with its inability to achieve primary endpoints during the induction phase. Notably, vidofludimus calcium showed a favorable safety and tolerability profile, reinforcing its potential in treating inflammatory bowel diseases. Despite some challenges in the induction phase, the findings support ongoing development of the therapy.
Read more →Immunic, Inc. has presented encouraging data from its Phase 1b clinical trial of IMU-856, an oral small molecule modulator targeting SIRT6 for the treatment of celiac disease. The trial showed positive effects on gut architecture and symptom improvement compared to placebo, with a favorable safety profile. These results suggest the potential for IMU-856 to become a groundbreaking therapy for celiac disease and other gastrointestinal disorders, with further Phase 2 testing planned.
Read more →Immunic, Inc. presented positive results from its Phase 2 EMPhASIS trial for vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS) at MSMilan2023. The treatment demonstrated a significant decrease in serum neurofilament light chain (NfL), indicating potential efficacy, even in patients without active disease. Additionally, the trial met its primary and key secondary endpoints with a safety profile comparable to that of placebo. This promising data supports further development of vidofludimus calcium as a potential neuroprotective treatment.
Read more →Immunic, Inc. has reported positive interim data from its Phase 2 CALLIPER trial of vidofludimus calcium in patients with progressive multiple sclerosis. The trial showed significant improvements in the serum neurofilament light chain (NfL) biomarker, indicating potential neuroprotective benefits beyond just anti-inflammatory effects. The results also highlight the medication's effectiveness across various subtypes of progressive MS. Further data from a larger patient cohort will be available in April 2025, with ongoing developments in the Phase 3 ENSURE program in relapsing multiple sclerosis.
Read more →Immunic, Inc. reported positive interim results from its Phase 2 CALLIPER trial of vidofludimus calcium in patients with progressive multiple sclerosis. The trial showed a significant reduction in serum neurofilament light chain (NfL) levels, indicating potential neuroprotective effects. The company anticipates further data in April 2025, which may solidify vidofludimus calcium's position as a novel treatment option.
Read more →Immunic, Inc. announced its participation in several scientific conferences taking place throughout October 2023. At the MSMilan2023 meeting, the company will present data from its phase 2 EMPhASIS trial focusing on vidofludimus calcium for multiple sclerosis. Additionally, Immunic's clinical team will showcase findings related to IMU-856, an epigenetic modulator for celiac disease, at the UEG Week, along with data from a trial on vidofludimus for ulcerative colitis. The company aims to highlight its innovations in treatment approaches for chronic inflammatory diseases through these events.
Read more →Immunic, Inc. has announced its participation in two upcoming industry conferences in September, including BioPharm America and the 2023 Cantor Global Healthcare Conference. Key executives will be representing the company, with a webcast available for those interested in its clinical developments. The company focuses on developing orally administered therapies for chronic inflammatory and autoimmune diseases, highlighted by its lead program, vidofludimus calcium. This program is currently in phase 3 and phase 2 trials and has shown therapeutic activity in earlier studies.
Read more →Immunic, Inc. has completed patient enrollment for its Phase 2 CALLIPER trial, which studies vidofludimus calcium in individuals with progressive multiple sclerosis. A total of 467 patients have been randomized to receive either the treatment or a placebo. An interim analysis of biomarker data is anticipated in fall 2023, and a comprehensive data readout is expected by April 2025. The trial is designed to explore the neuroprotective properties and efficacy of vidofludimus calcium in this patient demographic.
Read more →Immunic, Inc. reported its second quarter 2023 financial results, highlighting positive clinical data for its lead candidates, vidofludimus calcium and IMU-856. The company announced successful Phase 1b results for IMU-856 in celiac disease and ongoing trials for vidofludimus calcium in multiple sclerosis. With $77.3 million in cash, Immunic is well-positioned to fund its operations into the fourth quarter of 2024.
Read more →Immunic, Inc. announced robust progress in its clinical programs during Q2 2023, highlighting significant findings for vidofludimus calcium as a potential treatment for multiple sclerosis and promising results from its Phase 1 trial of IMU-856 for celiac disease. The firm is set to report interim results from a key MS trial in Fall 2023 and bolstered its financial standing with $77.3 million in cash reserves. Despite these advancements, the company faced increased net losses and rising R&D expenses.
Read more →Immunic, Inc. is participating in several key investor and scientific conferences in August 2023. Notably, at the International Congress of Neuroimmunology, Immunic will present preclinical data supporting the efficacy of vidofludimus calcium as a potential neuroprotective treatment for multiple sclerosis. The company's pipeline includes additional therapies aimed at chronic inflammatory and autoimmune diseases, with ongoing clinical trials for its leading drug candidate. This active conference participation reflects Immunic's commitment to advancing its innovative treatments and engaging with the scientific community.
Read more →Immunic, Inc. announced that it will release its financial results for the second quarter ending June 30, 2023, along with a corporate update on August 3, 2023. The company is developing small molecule therapies aimed at chronic inflammatory and autoimmune diseases, with key programs in various stages of clinical trials. The lead candidate, vidofludimus calcium, is progressing in both phase 3 and phase 2 trials, targeting relapsing and progressive multiple sclerosis. The announcement highlights the company's commitment to innovation and addressing significant health challenges.
Read more →Immunic, Inc. announced its participation in several scientific and investor conferences throughout July, including the Symposium 234 and the SVB Securities Therapeutics Forum. At these events, Immunic will present significant preclinical and clinical trial data related to its lead therapeutic candidate, IMU-856, aimed at treating celiac disease. Furthermore, the company will engage with key opinion leaders during a roundtable discussion on unmet medical needs in celiac disease. These activities reflect Immunic's commitment to advancing its clinical pipeline for treating chronic inflammatory diseases.
Read more →Immunic, Inc. announced its participation in significant scientific and investor conferences in June 2023, including the Consortium of Multiple Sclerosis Centers Annual Meeting and the BIO International Convention. At the CMSC meeting, Dr. Robert J. Fox will present data from the phase 2 EMPhASIS trial regarding vidofludimus calcium, a promising therapy for relapsing-remitting multiple sclerosis. Immunic's management will also engage in partnering activities at the BIO International Convention, reflecting ongoing efforts to advance their clinical pipeline for chronic inflammatory and autoimmune diseases.
Read more →Immunic, Inc. announced the publication of preclinical data confirming that vidofludimus calcium acts as a potent Nurr1 activator, indicating potential neuroprotective effects. This data supports its position as a leading treatment option for multiple sclerosis and other neurodegenerative diseases. The findings were published in the Journal of Medicinal Chemistry, indicating significant advancements in understanding the drug's benefits. Strong activation of Nurr1 by vidofludimus calcium may play a crucial role in reducing disability worsening in multiple sclerosis patients, as evidenced by earlier trial results.
Read more →Immunic, Inc. reported positive findings from its Phase 1b clinical trial of IMU-856 for celiac disease, demonstrating significant improvements in various disease markers compared to placebo. The company also highlighted encouraging results from its CALDOSE-1 trial of vidofludimus calcium in ulcerative colitis, showcasing strong activity and a favorable safety profile. With substantial cash reserves, Immunic is well-positioned to advance its development programs and explore additional clinical applications for its therapies.
Read more →Immunic, Inc. has announced the upcoming release of its financial results for the first quarter of 2023 and a corporate update, scheduled for May 11, 2023. The company, which focuses on orally administered therapies for chronic inflammatory and autoimmune diseases, will hold a webcast to discuss the results. Notably, their lead program, IMU-838, is currently in phase 3 trials for multiple sclerosis and has demonstrated potential therapeutic effects in earlier trials for related conditions. Additional details can be accessed on Immunic's website.
Read more →Immunic, Inc. presented new clinical and preclinical data for IMU-856 at Digestive Disease Week 2023, highlighting its role as a selective modulator of SIRT6, which aids in the regeneration of bowel epithelium and intestinal barrier function. Recent phase 1b data suggest IMU-856 offers significant improvements in managing celiac disease, with positive effects seen in histology, symptoms, biomarkers, and nutrient absorption. The compound demonstrates additional promise for treating other serious gastrointestinal diseases. A phase 2b clinical trial is planned to further assess its efficacy in celiac disease patients.
Read more →Immunic, Inc. announced positive results from its Phase 1b clinical trial of IMU-856 for celiac disease, demonstrating significant improvements in key aspects of the disease's pathology. The trial showed that IMU-856 can protect intestinal villi from gluten-induced damage and enhance nutrient absorption without targeting the immune system. This treatment could provide a novel therapeutic avenue not only for celiac disease but also for other gastrointestinal disorders. The company is preparing for Phase 2b testing and is exploring other potential applications for IMU-856.
Read more →Immunic, Inc. announced the appointment of Dr. Richard Rudick to its Board of Directors, effective April 26, 2023. Dr. Rudick, a recognized expert in multiple sclerosis with extensive experience in clinical research and pharmaceutical management, is expected to enhance the board's capability. This change comes as Vincent Ossipow steps down after seven years, with the company expressing gratitude for his contributions. Dr. Rudick's expertise will be particularly beneficial for the development of Immunic's lead treatment, vidofludimus calcium, among other initiatives.
Read more →Immunic, Inc. has appointed Dr. Richard Rudick, a respected figure in multiple sclerosis, to its board of directors. This addition is expected to bolster the company's expertise as it advances its clinical pipeline, particularly in relation to vidofludimus calcium, which is currently undergoing phase 3 trials. Dr. Rudick's extensive experience in clinical research and prior roles in significant institutions like Biogen and the Cleveland Clinic will be instrumental for Immunic's strategic goals. Vincent Ossipow, Ph.D., will step down from the board effective June 28, 2023, after seven years of service.
Read more →Immunic, Inc. reported positive data from the maintenance phase of its Phase 2 CALDOSE-1 trial for vidofludimus calcium in patients with moderate-to-severe ulcerative colitis. The trial demonstrated a dose-linear increase in clinical remission rates and endoscopic healing rates at the 30 mg dose. Impressively, the data indicated significant improvements compared to placebo, with a favorable safety profile consistent with past studies. In light of these results, Immunic plans to prioritize the development of vidofludimus calcium and IMU-856, while deprioritizing the izumerogant program.
Read more →Immunic, Inc. reported promising results from the maintenance phase of its Phase 2b CALDOSE-1 trial for vidofludimus calcium in patients with moderate-to-severe ulcerative colitis. The 30 mg once-daily dosage exhibited a statistically significant increase in clinical remission and endoscopic healing compared to placebo at week 50. Additionally, the trial data demonstrated that vidofludimus calcium had a favorable safety profile, with no new safety signals. However, the company has decided to deprioritize its izumerogant program in light of these results and will explore options for the UC program.
Read more →Immunic, Inc. reported its financial results for the year ended December 31, 2022, highlighting significant progress in its drug development pipeline. With a focus on vidofludimus calcium for multiple sclerosis, the company expects to release interim results from its Phase 2 CALLIPER trial in the second half of 2023. The firm also anticipates data from its Phase 1 clinical trial of IMU-856 in celiac disease in mid-2023. Despite challenges indicated by operational losses, Immunic maintains a healthy cash position to fund its initiatives into late 2024.
Read more →Immunic, Inc. announced promising results from the Phase 2 EMPhASIS trial of vidofludimus calcium in treating relapsing-remitting multiple sclerosis. The data, presented at the ACTRIMS Forum 2023, indicated a low rate of confirmed disability worsening over time when compared with historical data of existing treatments. The results from the trial’s ongoing open-label extension phase demonstrated high percentages of patients free from disability worsening following treatment. Immunic anticipates further insights from its ongoing Phase 3 ENSURE and Phase 2 CALLIPER trials, which could enhance the understanding of vidofludimus calcium's potential in MS treatment.
Read more →Immunic, Inc. has announced that it will release its financial results for the fourth quarter and the full year ended December 31, 2022, along with a corporate update on February 23, 2023. The company is focused on developing selective oral immunology therapies aimed at chronic inflammatory and autoimmune diseases. Notably, a webcast will follow the announcement at 8:00 am ET, allowing stakeholders to engage with the company's developments. The announcement also includes a cautionary note about forward-looking statements, highlighting potential risks and uncertainties in their operations and projections.
Read more →Immunic, Inc. will host a virtual Celiac Disease R&D Day on February 9, 2023. The event aims to address drug development pathways and the unmet medical needs associated with celiac disease. Key executives and opinion leaders will discuss the complexities of the disease and potential treatments. Immunic expects to release initial results from its ongoing phase 1 clinical trial of IMU-856 by mid-2023.
Read more →Immunic, Inc. (Nasdaq: IMUX) has announced its participation in several upcoming scientific and investor conferences in February 2023. These include a panel discussion on pharmacovigilance regulations, a webcast focused on celiac disease treatment options, and a presentation of data from the EMPhASIS trial for multiple sclerosis. The company's involvement in these conferences aims to showcase their clinical developments and enhance visibility in the biopharma sector.
Read more →Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential - Data Show Encouraging Signals for Vidofludimus Calcium for Preventing or Delaying Confirmed Disability Worse
Read more →NEW YORK, Nov. 10, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the fol
Read more →Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update $72.8 Million in Cash and Cash Equivalents as of September 30, 2022, Plus $56.4 Million of Net Cash Raised in October 2022 Expected to Fund Immunic Into the Fourth Quarter of 2024 - Webc
Read more →– Webcast to be Held at 8:00 am ET on November 3, 2022 – NEW YORK, Oct. 27, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and aut
Read more →Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate Interim Analysis Revealed Unexpected High Placebo Rate; Two Active Arms Did Not Separate From Placebo - No New Safety Signals Observed for IMU-935 in this Tri
Read more →Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing NEW YORK, October 10, 2022 - Immunic, Inc. (Nasdaq: IMUX) ("Immunic" or the "Company"), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therap
Read more →NEW YORK, Oct. 4, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the foll
Read more →– Unblinded Data Revealed a Favorable Safety, Tolerability and Pharmacokinetic Profile for IMU‑856 in Single and 14-Day Multiple Dosing – – No Maximum Tolerated Dose Reached; Investigated Doses Expected to Exceed Required Therapeutic Dosing of IMU-856 – – Third Portion of Phase
Read more →Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects Unblinded Data Revealed a Favorable Safety, Tolerability and Pharmacokinetic Profile for IMU-856 in Single and 14-Day Multiple Do
Read more →NEW YORK, Sept. 1, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the fol
Read more →NEW YORK, Aug. 16, 2022 /PRNewswire/ -- Immunic, Inc. (NASDAQ: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company has rec
Read more →Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update Initial Clinical Activity Results of IMU-935 in Psoriasis Expected in the Fourth Quarter - Unblinded Safety Data from the Single and Multiple Ascending Dose Parts of Phase 1 Clinical Tr
Read more →NEW YORK, Aug. 2, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D.,
Read more →– Webcast to be Held at 8:00 am ET on August 4, 2022 – NEW YORK, July 28, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoi
Read more →Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria T rns n Global Commercial Executive Brings 20 Years of Sales and Marketing Expertise - Jan Van den Bossche Steps Down from Board After Six Year Tenure - July 6, 2022 - Immunic, Inc. (Nasdaq: IMUX),
Read more →NEW YORK, June 28, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the fol
Read more →NEW YORK, June 15, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that data from its phase
Read more →NEW YORK, June 8, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the foll
Read more →– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and Concurrent Use of Corticosteroids – – In UC Population Without Concurrent Steroid Use, Pooled Vidofludimus Calcium Data Suggest A
Read more →Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected I
Read more →Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis Expected Next Month - Part C Portion of Phase 1 Trial of IMU-935 in Psoriasis P
Read more →– First Time Patients Will be Treated with the Company's Orally Available Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium – NEW YORK, May 5, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage bio
Read more →– Webcast to be Held at 8:00 am ET on May 10, 2022 – NEW YORK, May 3, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmun
Read more →NEW YORK, April 25, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the fo
Read more →NEW YORK, March 16, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that Glenn Whaley, CPA,
Read more →NEW YORK, March 8, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the fol
Read more →Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity Initiated Enrollment in Phase 3 ENSURE Program of Vidofludimus Calcium for the Treatment of Relapsing Multiple Sclerosis; Final Cohort 2 Data from the Phase 2 EMPhASIS Trial Confirms Phase 3
Read more →Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis Top-Line Data of the
Read more →NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will re
Read more →NEW YORK, Feb. 8, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the follow
Read more →NEW YORK, Feb. 2, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company received
Read more →Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor Unblinded Data Established a Favorable Safety and Tolerability Profile for IMU-935 in Single Do
Read more →NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced enrollment of the first p
Read more →NEW YORK, Nov. 23, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D.,
Read more →NEW YORK, Nov. 18, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the first patient enroll
Read more →Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity - Fully Enrolled Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis - - Initiated Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, Intended to Run Conc
Read more →NEW YORK, Nov. 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will rel
Read more →NEW YORK, Oct. 28, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the final patient has been
Read more →NEW YORK, Oct. 27, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced enrollment of the first
Read more →NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Wal
Read more →NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced enrollment of the first
Read more →NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the fo
Read more →NEW YORK and GOETTINGEN, Germany, Sept. 22, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced
Read more →NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the fol
Read more →Immunic, Inc. Reports Second Quarter 2021 and Highlights Recent Activity Received FDA Clearance to Initiate Twin IMU-838 Phase 3 ENSURE Trials in Relapsing-Remitting Multiple Sclerosis and Supportive Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis - Reported In Vitro
Read more →NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the foll
Read more →NEW YORK, July 19, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the closing of
Read more →NEW YORK, July 15, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the pric
Read more →NEW YORK, July 14, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that it
Read more →Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class ROR t Inverse Agonist IMU-935 Has Been Observed In Vitro to Inhibit the Generation of Th17 Cells and Production of IL-17 Cytokine
Read more →Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating
Read more →NEW YORK, June 28, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the follo
Read more →NEW YORK, June 10, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the follo
Read more →NEW YORK, June 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the appointment of Inderpal Singh
Read more →Immunic, Inc. Reports First Quarter 2021 and Highlights Recent Activity EMPhASIS Cohort 2 Interim Analysis Confirmed 30 mg Dose of IMU-838 as Most Appropriate for Planned Phase 3 Program in Relapsing-Remitting Multiple Sclerosis, Expected to Begin in the Second Half of 2021 -
Read more →NEW YORK, April 15, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced interim data from Cohort 2 of i
Read more →NEW YORK, April 13, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the foll
Read more →Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838 and PLANEGG-MARTINSRIED, Germany, March 31, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective
Read more →NEW YORK, March 2, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management's participation
Read more →Immunic, Inc. Reports Year End 2020 Financial and Highlights Recent Activity Phase 3 Program of IMU-838 in Relapsing-Remitting Multiple Sclerosis Expected to Begin in the Second Reported Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial
Read more →Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial of IMU-838 Confirmed Based on Multiple Secondary Endpoints, Including Clinically Meaningful Improvements in Time to Clinical Recovery and Clin
Read more →NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced positive top-line data fro
Read more →NEW YORK, Feb. 11, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., C
Read more →NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management's participation
Read more →NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it has been selected
Read more →NEW YORK, Nov. 24, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management's participation
Read more →NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the formation of a Scienti
Read more →NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management's participation
Read more →Immunic, Inc. Reports Third Quarter 2020 and Provides Corporate Update Released Very Positive Phase 2 Data for IMU-838 in Relapsing-Remitting Multiple Sclerosis; Company to Submit End-of-Phase 2 Meeting Requests to Regulatory Authorities at the End of Q1 2021 - 200 Patients R
Read more →NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that the company has enroll
Read more →EIB Provides Immunic With up to 24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy Luxembourg, Gr felfing, Germany and New York, October 20, 2020 - The European Investment Bank (EIB) and Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical
Read more →NEW YORK, Sept. 29, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the foll
Read more →NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the results of a pre-plan
Read more →Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020 Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppress
Read more →NEW YORK, Sept. 11, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that the full unblinded c
Read more →NEW YORK, Sept. 8, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the follo
Read more →NEW YORK, Aug. 20, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced dosing of the first health
Read more →NEW YORK, Aug. 10, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten p
Read more →NEW YORK, Aug. 4, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the pricing of an underwrit
Read more →NEW YORK, Aug. 3, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it intends to offer an
Read more →Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple
Read more →NEW YORK, July 30, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it will report financial re
Read more →Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19 Study Being Conducted in Collaboration with University Hospitals Coventry
Read more →NEW YORK, June 22, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the company is set to join
Read more →Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19 YORK, June 15, 2020 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inf
Read more →Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock NEW YORK, June 10, 2020 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and
Read more →NEW YORK, June 9, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced receipt of regulatory allowance f
Read more →NEW YORK, May 29, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's participation in the
Read more →Inc. to Host Virtual R&D Day Today, May 19, 2020 Presentation Will Include Preclinical Data of IMU-838 Against SARS-CoV-2 as Well as First Pharmacokinetic Data From the Ongoing Phase 1 Clinical Trial of IMU-935 - Live Webcast to be Held From 9:00 am to 1:00 pm ET - YORK, May
Read more →NEW YORK, May 19, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that it will host a virtual R&D Day tod
Read more →Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients YORK, May 13, 2020 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company fo
Read more →Immunic, Inc. Reports First Quarter 2020 and Highlights Recent Activity YORK, May 8, 2020 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune dis
Read more →Immunic, Inc. Announces Pricing of $15 NEW YORK, April 23, 2020 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced tha
Read more →Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients - In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit
Read more →NEW YORK, April 17, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced a series of changes to its Exec
Read more →Inc. Reports Year End 2019 Financial Results and - Top-Line Data from Phase 2 EMPhASIS Trial in Relapsing-Remitting Multiple Sclerosis Expected in Third Quarter 2020 - - Cash of $29.4 Million Provides Funding Through Key 2020 Inflection Points - NEW YORK, March 16, 2020 - I
Read more →NEW YORK, Feb. 11, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's participation in th
Read more →NEW YORK, Jan. 8, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that its subsidiary, Immunic AG,
Read more →NEW YORK, Dec. 4, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Hella Kohlhof, Ph.D., Chief Scient
Read more →NEW YORK, Nov. 25, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's participation in th
Read more →NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Barclay "Buck
Read more →Immunic, Inc. Reports Third Quarter 2019 and Highlights Recent Activity NEW YORK, November 7, 2019 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and auto
Read more →SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's participation in th
Read more →SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamar Howson
Read more →SAN DIEGO, Oct. 10, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that the final patient was enrolled a
Read more →SAN DIEGO, Sept. 30, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's parti
Read more →SAN DIEGO, Sept. 18, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced dosing of the firs
Read more →SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Andreas Muehler, M.
Read more →Immunic, Inc.'s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective - Unblinded Data Review Committee Recommended Continuation of the Lowest,
Read more →SAN DIEGO, Aug. 12, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced enrollment of the f
Read more →Immunic, Inc. Reports Second Quarter 2019 Financial Results and Highlights Recent Activity DIEGO, August 8, 2019 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class oral therapies for the treatment of chron
Read more →SAN DIEGO, Aug. 1, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the German Fede
Read more →SAN DIEGO, July 30, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, P
Read more →UPDATED UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On January 6, 2019, Vital Therapies, Inc., or Vital Therapies, a Delaware corporation, and Immunic AG, or Immunic, a stock corporation formed under the laws of Germany focused on developing novel oral therap
Read more →SAN DIEGO, July 16, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of
Read more →SAN DIEGO, June 24, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Hella Kohlhof, Ph.D.
Read more →Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update - Phase 2 Trial in Relapsing-Remitting Multiple Sclerosis Expected to be the First Efficacy Rea
Read more →Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2nd Conference on Molecular Mechanisms of Inflammation in - Results confirm IMU-935 as a potent inverse agonist of RORgt with an IC50 of 24 nM, leading to potent inhibition of
Read more →SAN DIEGO, May 30, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's participation in a
Read more →SAN DIEGO, May 9, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that management will participate
Read more →SAN DIEGO, April 29, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. S
Read more →Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Developing Oral Therapies with Best-in-Class Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis and Relapsing-Remitt
Read more →SAN DIEGO and PLANEGG-MARTINSRIED, Germany, April 12, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), today announced the completion of its stock-for-stock exchange transaction with Vital Therapies, Inc. (Nasdaq: VTL, through April 12, 2019). The company has been renamed Immun
Read more →INVESTMENT AND SUBSCRIPTION AGREEMENT Dated as of January 6, 2019 Article 1. DESCRIPTION OF THE CONCURRENT FINANCING 2 1.1 Immunic Shareholders' Meeting 2 1.2 Pre-Closing Capital Increase 3 1.3 Contributions to Immunic's Capital Reserves 5 1.4 Use of Proceeds. 6 1.5 Further Act
Read more →VITAL THERAPIES ANNOUNCES THIRD QUARTER 2015 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE SAN DIEGO, November 5, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD , a cell-based therapy targeting the treatment of liver fai
Read more →Vital Therapies provides corporate update and announces date of third quarter 2015 financial results SAN DIEGO, October 16, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD , a cell-based therapy targeting the treatment of
Read more →Vital Therapies Outlines Plans for New Phase 3 Trial of ELAD(R) in Alcohol-Induced Liver Decompensation SAN DIEGO, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD , a cell-based therapy targeting the treatment of li
Read more →Vital Therapies Announces additional data from vti-208 presented at ROSTOCK CONFERENCE SAN DIEGO, August 31, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD , a cell-based therapy targeting the treatment of liver failure,
Read more →VITAL THERAPIES ANNOUNCES THAT TOPLINE RESULTS OF VTI-208 FAIL TO ACHIEVE PRIMARY OR SECONDARY ENDPOINTS OF IMPROVEMENT IN OVERALL SURVIVAL PRE-SPECIFIED EXPLORATORY SUBSET ANALYSES SUGGEST EFFICACY TRENDS SAN DIEGO, August 21, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (N
Read more →VITAL THERAPIES REPORTS ON CLINICAL TRIAL PROGRESS AND EU REGULATORY ADVICE San Diego, Calif. July 9, 2014 Vital Therapies, Inc. (NASDAQ:VTL), a biotherapeutic company developing ELAD , a cell-based therapy targeting treatment of acute liver failure, is providing this update on
Read more →VITAL THERAPIES ANNOUNCES FIRST QUARTER 2014 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE Diego, Calif. May 28, 2014 Vital Therapies, Inc. (NASDAQ:VTL), a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, today announced
Read more →VITAL THERAPIES ANNOUNCES FULL EXERCISE OF UNDERWRITERS OPTION TO PURCHASE ADDITIONAL SHARES San Diego, Calif. May 6, 2014 Vital Therapies, Inc. (NASDAQ:VTL), a biotherapeutic company developing a cell-based therapy targeting treatment of all forms of acute liver failure, toda
Read more →VITAL THERAPIES, INC. REACHES MIDPOINT FOR ENROLLMENT IN VTI-208 SAN DIEGO, CA (Marketwire May 1, 2014) Vital Therapies, Inc., a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, today announced that the 100th subject has bee
Read more →